A
drug used to prevent or treat certain bone problems. Under the brand name
Xgeva, it is used to prevent broken bones and other bone problems caused by solid tumors that have metastasized (spread) to bone. Under the brand name
Prolia, it is used to treat
osteoporosis (a decrease in
bone mass and density) in
postmenopausal women who have a high risk of breaking bones. Xgeva binds to a
protein called RANKL, which keeps RANKL from binding to another protein called RANK on the surface of certain bone cells. This may help keep bone from breaking down. Xgeva is a type of monoclonal
antibody. Also called
AMG 162,
denosumab, and Prolia.
AMG 162
A drug used to prevent or treat certain bone problems. Under the brand name Xgeva, it is used to prevent broken bones and other bone problems caused by solid tumors that have metastasized (spread) to bone. Under the brand name Prolia, it is used to treat osteoporosis (a decrease in bone mass and density) in postmenopausal women who have a high risk of breaking bones. AMG 162 binds to a protein called RANKL, which keeps RANKL from binding to another protein called RANK on the surface of certain bone cells. This may help keep bone from breaking down. AMG 162 is a type of monoclonal antibody. Also called denosumab, Prolia, and Xgeva.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
antibody (AN-tee-BAH-dee)
A protein made by plasma cells (a type of white blood cell) in response to an antigen (a substance that causes the body to make a specific immune response). Each antibody can bind to only one specific antigen. The purpose of this binding is to help destroy the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
bone mass (bone mas)
A measure of the amount of minerals (mostly calcium and phosphorous) contained in a certain volume of bone. Bone mass measurements are used to diagnose osteoporosis (a condition marked by decreased bone mass), to see how well osteoporosis treatments are working, and to predict how likely the bones are to break. Low bone mass can occur in patients treated for cancer. Also called BMD, bone density, and bone mineral density.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
denosumab (deh-noh-SOO-mab)
A drug used to prevent or treat certain bone problems. Under the brand name Xgeva, it is used to prevent broken bones and other bone problems caused by solid tumors that have metastasized (spread) to bone. Under the brand name Prolia, it is used to treat osteoporosis (a decrease in bone mass and density) in postmenopausal women who have a high risk of breaking bones. Denosumab binds to a protein called RANKL, which keeps RANKL from binding to another protein called RANK on the surface of certain bone cells. This may help keep bone from breaking down. Denosumab is a type of monoclonal antibody. Also called AMG 162, Prolia, and Xgeva.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
drug (drug)
Any substance, other than food, that is used to prevent, diagnose, treat or relieve symptoms of a disease or abnormal condition. Also refers to a substance that alters mood or body function, or that can be habit-forming or addictive, especially a narcotic.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
osteoporosis (OS-tee-oh-puh-ROH-sis)
A condition that is marked by a decrease in bone mass and density, causing bones to become fragile.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
postmenopausal (post-MEH-nuh-PAW-zul)
Having to do with the time after menopause. Menopause (“change of life”) is the time in a woman's life when menstrual periods stop permanently.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
Prolia (PROH-lee-uh)
A drug used to prevent or treat certain bone problems. Under the brand name Xgeva, it is used to prevent broken bones and other bone problems caused by solid tumors that have metastasized (spread) to bone. Under the brand name Prolia, it is used to treat osteoporosis (a decrease in bone mass and density) in postmenopausal women who have a high risk of breaking bones. Prolia binds to a protein called RANKL, which keeps RANKL from binding to another protein called RANK on the surface of certain bone cells. This may help keep bone from breaking down. Prolia is a type of monoclonal antibody. Also called AMG 162, denosumab, and Xgeva.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
protein (PROH-teen)
A molecule made up of amino acids that are needed for the body to function properly. Proteins are the basis of body structures such as skin and hair and of substances such as enzymes, cytokines, and antibodies.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
Xgeva (ex-JEE-vuh)
A drug used to prevent or treat certain bone problems. Under the brand name Xgeva, it is used to prevent broken bones and other bone problems caused by solid tumors that have metastasized (spread) to bone. Under the brand name Prolia, it is used to treat osteoporosis (a decrease in bone mass and density) in postmenopausal women who have a high risk of breaking bones. Xgeva binds to a protein called RANKL, which keeps RANKL from binding to another protein called RANK on the surface of certain bone cells. This may help keep bone from breaking down. Xgeva is a type of monoclonal antibody. Also called AMG 162, denosumab, and Prolia.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)